Comparative Pharmacology
Head-to-head clinical analysis: DANTROLENE SODIUM versus PARAFLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DANTROLENE SODIUM versus PARAFLEX.
DANTROLENE SODIUM vs PARAFLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dantrolene sodium dissociates the excitation-contraction coupling in skeletal muscle by inhibiting calcium release from the sarcoplasmic reticulum via ryanodine receptor blockade.
Centrally acting muscle relaxant; inhibits polysynaptic reflexes at the spinal cord level, possibly by depressing the central nervous system.
25 mg orally once daily for 7 days; then 25 mg three times daily for 7 days; then 50 mg three times daily for 7 days; then 100 mg three times daily. Maximum daily dose: 400 mg. For malignant hyperthermia: 1 mg/kg intravenously, may repeat up to cumulative dose of 10 mg/kg.
250-500 mg orally once daily, may increase to 500 mg twice daily if needed. Maximum 500 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 8-10 hours in adults; may be prolonged to 12-15 hours in elderly or patients with hepatic impairment. Steady-state achieved in 3-4 days.
Terminal elimination half-life is approximately 2–3 hours, allowing for multiple daily dosing.
Primarily hepatic metabolism; approximately 25% excreted in urine as metabolites, 45-50% in feces via bile; less than 1% unchanged in urine.
Renal excretion of unchanged drug and metabolites accounts for approximately 50% of an oral dose; fecal excretion accounts for about 20%.
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant